Trump Announces Weight-Loss Drug Pricing Deal
Celebrity Pictures > Archives > 2025 > November >
Trump Announces Weight-Loss Drug Pricing Deal (58 pictures)
View All Images- United States Secretary of Health and Human Services Robert F. Kennedy, Jr, speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Chart on drug pricing in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States House Majority Whip Tom Emmer (Republican of Minnesota), from left, US President Donald Trump, and Heidi Overton, White House domestic policy council, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mike Doustdar, chief executive officer of Novo Nordisk A/S, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mike Doustdar, chief executive officer of Novo Nordisk A/S, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mike Doustdar, chief executive officer Novo Nordisk A/S, from left, David Ricks, chief executive officer of Eli Lilly & Co., and Howard Lutnick, US commerce secretary, stand behind US President Donald Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Chris Klomp, deputy administrator of the Centers for Medicare and Medicaid, left, and Mehmet Oz, Administrator, Centers for Medicare and Medicaid Services (CMMS), speak in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Martin A Makary, Commissioner, US Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Chris Klomp, deputy administrator of the Centers for Medicare and Medicaid, speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, from left, David Ricks, chief executive officer of Eli Lilly & Co., and Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- David Ricks, chief executive officer of Eli Lilly & Co., speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump, center, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States Secretary of Health and Human Services Robert F. Kennedy, Jr, speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Robert F. Kennedy Jr., US secretary of Health and Human Services (HHS), left, and Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- David Moore, executive vice president of US Operations at Novo Nordisk A/S, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mehmet Oz, Administrator, Centers for Medicare and Medicaid Services (CMMS), speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mike Doustdar, chief executive officer Novo Nordisk A/S, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mehmet Oz, Administrator, Centers for Medicare and Medicaid Services (CMMS), speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mike Doustdar, chief executive officer of Novo Nordisk A/S, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States Secretary of Commerce Howard Lutnick, and US President Donald Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump, center, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Chris Klomp, deputy administrator of the Centers for Medicare and Medicaid, speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States Secretary of Health and Human Services Robert F. Kennedy, Jr, speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump, center, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- David A Ricks, chief executive officer of Eli Lilly & Co. makes remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump applauds in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Heidi Overton, White House domestic policy council, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump speaks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- US President Donald Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Robert F. Kennedy Jr., US secretary of Health and Human Services (HHS), left, and Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Photographer: Aaron Schwartz/Bloomberg Credit: Aaron Schwartz / Pool via CNP/AdMedia
- United States President Donald J Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- US President Donald Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- The presidential seal on a rug in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- US President Donald Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, from left, Robert F. Kennedy Jr., US secretary of Health and Human Services (HHS), and Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A boom microphone in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- US President Donald Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- US President Donald Trump in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- A man faints as US President Donald Trump gives remarks in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia
- Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Credit: Aaron Schwartz / Pool via CNP/AdMedia `